Chandler Dora1, Gina M Clarke2, Gregory Frey3, David Sella3. 1. Department of Urology, Mayo Clinic Florida, Jacksonville, Florida, USA. 2. Clinical Science, Profound Medical, Mississauga, Canada. 3. Department of Radiology, Mayo Clinic Florida, Jacksonville, Florida, USA.
Abstract
Purpose: MRI-guided transurethral ultrasound ablation (TULSA) uses real-time MR thermometry feedback to target prostate disease. We systematically review the literature to synthesize efficacy, functional, and safety outcomes and assess the influence of planned ablation fraction on outcome. Materials and Methods: PubMed, Embase, and the Cochrane Library were searched from inception to June 2021 following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies reporting at least one efficacy, functional, or safety outcome after a single TULSA treatment were included. The relationship of freedom from salvage treatment and potency preservation with planned ablation volume was modeled. Results: Two hundred twenty-four patients were treated in 10 studies with up to a 5-year follow-up, mainly for primary localized prostate cancer (PCa) plus smaller cohorts with recurrent PCa, and locally advanced PCa (LAPC). The prostate-specific antigen decline from baseline up to 2 years, including focal to whole-gland ablation plans, was 54% to 97%. The rate of salvage treatment after one TULSA treatment for primary PCa was 7% to 17%. Continence and potency preservation were from 92% to 100% and from 75% to 98%. Urinary symptoms were stable in men with good voiding function at baseline, and 85% of men with concurrent PCa and lower urinary tract symptoms met the criteria for improvement. Symptom relief in a small cohort of men with LAPC was observed. Grade III adverse events were incurred by 13/224 men (6%), with no rectal injury/fistula or Grade IV complication. The planned ablation fraction was linearly related to salvage-free survival. The relationship between potency preservation and planned ablation fraction followed a sigmoid curve. Conclusions: As an alternative to conventional treatments, TULSA is safe and effective for prostate tissue ablation in men with primary PCa. There is also evidence that TULSA delivers effective relief of urinary symptoms while treating PCa in a single, low-morbidity procedure. The likelihood of freedom from additional treatment or potency preservation is associated with the planned ablation fraction.
Purpose: MRI-guided transurethral ultrasound ablation (TULSA) uses real-time MR thermometry feedback to target prostate disease. We systematically review the literature to synthesize efficacy, functional, and safety outcomes and assess the influence of planned ablation fraction on outcome. Materials and Methods: PubMed, Embase, and the Cochrane Library were searched from inception to June 2021 following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies reporting at least one efficacy, functional, or safety outcome after a single TULSA treatment were included. The relationship of freedom from salvage treatment and potency preservation with planned ablation volume was modeled. Results: Two hundred twenty-four patients were treated in 10 studies with up to a 5-year follow-up, mainly for primary localized prostate cancer (PCa) plus smaller cohorts with recurrent PCa, and locally advanced PCa (LAPC). The prostate-specific antigen decline from baseline up to 2 years, including focal to whole-gland ablation plans, was 54% to 97%. The rate of salvage treatment after one TULSA treatment for primary PCa was 7% to 17%. Continence and potency preservation were from 92% to 100% and from 75% to 98%. Urinary symptoms were stable in men with good voiding function at baseline, and 85% of men with concurrent PCa and lower urinary tract symptoms met the criteria for improvement. Symptom relief in a small cohort of men with LAPC was observed. Grade III adverse events were incurred by 13/224 men (6%), with no rectal injury/fistula or Grade IV complication. The planned ablation fraction was linearly related to salvage-free survival. The relationship between potency preservation and planned ablation fraction followed a sigmoid curve. Conclusions: As an alternative to conventional treatments, TULSA is safe and effective for prostate tissue ablation in men with primary PCa. There is also evidence that TULSA delivers effective relief of urinary symptoms while treating PCa in a single, low-morbidity procedure. The likelihood of freedom from additional treatment or potency preservation is associated with the planned ablation fraction.
Authors: Timothy J Wilt; Karen M Jones; Michael J Barry; Gerald L Andriole; Daniel Culkin; Thomas Wheeler; William J Aronson; Michael K Brawer Journal: N Engl J Med Date: 2017-07-13 Impact factor: 91.245
Authors: J L Stanford; Z Feng; A S Hamilton; F D Gilliland; R A Stephenson; J W Eley; P C Albertsen; L C Harlan; A L Potosky Journal: JAMA Date: 2000-01-19 Impact factor: 56.272
Authors: Shiva M Nair; Gencay Hatiboglu; James Relle; Khalil Hetou; Jason Hafron; Christopher Harle; Zahra Kassam; Robert Staruch; Mathieu Burtnyk; David Bonekamp; Heinz-Peter Schlemmer; Matthias C Roethke; Maya Mueller-Wolf; Sascha Pahernik; Joseph L Chin Journal: BJU Int Date: 2020-10-09 Impact factor: 5.588
Authors: Laurence Klotz; Christian P Pavlovich; Joseph Chin; Gencay Hatiboglu; Michael Koch; David Penson; Steven Raman; Aytekin Oto; Jurgen Fütterer; Marc Serrallach; James Relle; Yair Lotan; Axel Heidenreich; David Bonekamp; Masoom Haider; Temel Tirkes; Sandeep Arora; Katarzyna J Macura; Daniel N Costa; Thorsten Persigehl; Allan J Pantuck; Joyce Bomers; Mathieu Burtnyk; Robert Staruch; Scott Eggener Journal: J Urol Date: 2020-10-06 Impact factor: 7.450
Authors: Mikael Anttinen; Pietari Mäkelä; Pertti Nurminen; Eemil Yli-Pietilä; Visa Suomi; Teija Sainio; Jani Saunavaara; Pekka Taimen; Roberto Blanco Sequeiros; Peter J Boström Journal: Scand J Urol Date: 2020-09-08 Impact factor: 1.612
Authors: Massimo Valerio; Yannick Cerantola; Scott E Eggener; Herbert Lepor; Thomas J Polascik; Arnauld Villers; Mark Emberton Journal: Eur Urol Date: 2016-08-29 Impact factor: 20.096
Authors: Amir H Lebastchi; Arvin K George; Thomas J Polascik; Jonathan Coleman; Jean de la Rosette; Baris Turkbey; Bradford J Wood; Michael A Gorin; Abhinav Sidana; Sangeet Ghai; Kae Jack Tay; John F Ward; Rafael Sanchez-Salas; Berrend G Muller; Bernard Malavaud; Pierre Mozer; Sebastien Crouzet; Peter L Choyke; Osamu Ukimura; Ardeshir R Rastinehad; Peter A Pinto Journal: Eur Urol Date: 2020-06-10 Impact factor: 20.096
Authors: Mikael Anttinen; Pietari Mäkelä; Antti Viitala; Pertti Nurminen; Visa Suomi; Teija Sainio; Jani Saunavaara; Pekka Taimen; Roberto Blanco Sequeiros; Peter J Boström Journal: Eur Urol Open Sci Date: 2020-11-25